Capricor Therapeutics and CureDuchenne to Host Webinar on November 3, 2015 at 3:00 p.m. ET
Presentation to Discuss Capricor’s HOPE-Duchenne Trial
Capricor Therapeutics, Inc. (Nasdaq: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics and CureDuchenne, a national nonprofit organization dedicated to finding a cure for Duchenne muscular dystrophy, invite participants to join a webinar “HOPE-Duchenne: A Clinical Trial for Individuals with Heart Disease Related to DMD” on Tuesday, November 3, 2015 at 3:00 p.m. ET/noon PT.
- John Jefferies, MD, Study Principal Investigator, Cincinnati Children’s Hospital Medical Center
- Linda Marban, PhD, CEO Capricor, Inc.
- Brian Fedor, Study Manager, Capricor, Inc.
- Debra Miller, Founder and Chief Executive Officer of CureDuchenne
- Dr. Michael Kelly, PhD, Chief Scientific Advisor for CureDuchenne
Capricor is testing an investigational cardiac cell therapy to determine if reducing the amount of scar tissue in the heart can lead to better outcomes in Duchenne muscular dystrophy. The HOPE-Duchenne trial will evaluate if an investigational cardiac cell therapy is safe and potentially effective in treating boys and young men with Duchenne. The HOPE-Duchenne trial will study the amount of scar tissue in the heart muscle before and after treatment with either the investigational cardiac cell therapy or usual care. The webinar will provide an overview of the clinical trial which is being conducted at several sites in the U.S. To find a site, see the list on www.ClinicalTrials.gov (Study Identifier NCT02485938).
The HOPE-Duchenne trial will evaluate CAP-1002 for the first time in patients with Duchenne with significant cardiac dysfunction. CAP-1002 is Capricor's allogeneic, cardiosphere-derived cell (CDC) therapy already in clinical development for the treatment of heart disease. CureDuchenne Ventures invested in Capricor to support the development of its clinical program for Duchenne. Heart failure is the leading cause of death in patients with Duchenne.
To join the webinar please call (844-337-8088) and enter conference ID number 71482322. Visit here: https://cc.readytalk.com/cc/s/registrations/new?cid=sqpn7mtweznr to register online.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics. Our lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: CAP-1002, a cardiac cell therapy and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information visit www.capricor.com.
About CureDuchenne Ventures and CureDuchenne
CureDuchenne Ventures LLC collaborates with pharmaceutical and biotechnology companies to facilitate the development of drugs to treat Duchenne muscular dystrophy. CureDuchenne Ventures LLC was formed by CureDuchenne, a national nonprofit that has a successful track record of supporting research and raising awareness of the disease.
CureDuchenne was founded in 2003 with a focus on saving the lives of those with Duchenne muscular dystrophy, a disease that affects more than 300,000 boys worldwide. With support from CureDuchenne, three pharmaceutical treatments could be approved by the FDA within the next year. These treatments may lessen the effects of the disease for those with certain mutations of Duchenne, but there is still much to be done to find a cure. For more information, please visit CureDuchenne.org and follow us on Facebook, Twitter and YouTube.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; scope, duration, validity and enforceability of intellectual property rights; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on March 16, 2015, in our Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 25, 2015 and in our Quarterly Report on Form 10-Q for the period ending June 30, 2015, as filed with the Securities and Exchange Commission on August 14, 2015. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.
# # #